Bavarian Nordic - Articles and news items

Positive Phase I results for preventive Ebola vaccine regimen

Industry news / 20 April 2016 / Victoria White, Digital Content Producer

Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic…

Bavarian Nordic initiates Phase 1 clinical trial of MVA-BN RSV vaccine

Industry news / 18 August 2015 / Victoria White

Bavarian Nordic has initiated a Phase 1 clinical study of its MVA-BN vaccine candidate against respiratory syncytial virus (RSV)…

Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV

Industry news / 15 July 2015 / Victoria White

Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV…

Bavarian Nordic receives bulk order for Imvamune smallpox vaccine

Industry news / 7 July 2015 / Victoria White

BARDA, a division of the US Department of Health & Human Services, has ordered a bulk supply of Bavarian Nordic’s Imvamune non-replicating smallpox vaccine…

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Industry news / 13 May 2015 / Victoria White

EIB has reaffirmed its commitment to respond to the Ebola pandemic by providing a EUR 50m loan to Bavarian Nordic for accelerated development of a vaccine…

Bavarian Nordic announces positive results from pivotal Phase 3 study of IMVAMUNE smallpox vaccine

Industry news / 13 May 2015 / Victoria White

Results from a Phase 3 study of the liquid-frozen formulation of IMVAMUNE support a Biologics License Application for US approval of the vaccine…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+